A much better dynamic than expected at the start of the financial year
The veterinary laboratory, despite a basis of comparison which has become high, published quarterly activity in very strong growth.
On the stock market, the trend was less positive for Virbac shares since January 1, but the latest publication is now widely welcomed. Thus, in the first quarter, the group achieved a turnover of 318 million euros, organic growth of 16.2%.
In terms of species, pets, which represent 57.7% of billings, continued to accelerate with an increase of 19.5%, supported by the petfood ranges, dermatology and hygiene, as well as vaccines for dogs and cats. Production animals saw their sales remain at a high level, with an increase of 13.3%.
Remarkable performance in all regions
While there was fear of a slowdown in Asia-Pacific due to the health situation in China, the region posted growth of 22.5%, thanks to the Indian and Australian markets. These two countries generated 80% of the growth over the period and did more than compensate for the withdrawal of the Middle Kingdom, which suffered in addition to a basis of comparison.